Evidence map›Paper›PMID 23940658›Full record

ArticlePloS one2013

Neurotoxicity of prion peptides mimicking the central domain of the cellular prion protein.

Silvia Vilches, Cristina Vergara, Oriol Nicolás, Gloria Sanclimens, Sandra Merino, Sonia Varón, Gerardo A Acosta, Fernando Albericio, Miriam Royo, José A Del Río and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Silvia VilchesMolecular and Cellular Neurobiotechnology, Institute for Bioengineering of Catalonia, Barcelona, Spain.
Cristina Vergara
Oriol Nicolás
Gloria Sanclimens
Sandra Merino
Sonia Varón
Gerardo A Acosta
Fernando Albericio
Miriam Royo
José A Del Río
Rosalina Gavín
Universitat de Barcelona · ESBarcelona Biomedical Research Park · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESInstitute for Bioengineering of Catalonia · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ESInstitute for Research in Biomedicine · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The physiological functions of PrP(C) remain enigmatic, but the central domain, comprising highly conserved regions of the protein may play an important role. Indeed, a large number of studies indicate that synthetic peptides containing residues 106-126 (CR) located in the central domain (CD, 95-133) of PrP(C) are neurotoxic. The central domain comprises two chemically distinct subdomains, the charge cluster (CC, 95-110) and a hydrophobic region (HR, 112-133). The aim of the present study was to establish the individual cytotoxicity of CC, HR and CD. Our results show that only the CD peptide is neurotoxic. Biochemical, Transmission Electron Microscopy and Atomic Force Microscopy experiments demonstrated that the CD peptide is able to activate caspase-3 and disrupt the cell membrane, leading to cell death.

Indexed as

Amino Acid SequenceAnimalsApoptosisBenzothiazolesCaspase 3Cell Membrane PermeabilityCells, CulturedDimyristoylphosphatidylcholineEnzyme ActivationFluorescent DyesKineticsLipid BilayersMiceMice, 129 StrainMice, Inbred C57BLMice, KnockoutBenzothiazolesCasp3 protein, mouseCaspase 3DimyristoylphosphatidylcholineFluorescent DyesLipid BilayersPeptide FragmentsPrPC ProteinsThiazolesthioflavin T

Identifiers

PMID23940658
PMCPMC3733940
OpenAlexW1984267792

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.